|
$208,662
|
To analyze the characteristics and consequences of off patent, non-competitive drugs, and assist policymakers in developing policy proposals to address price spikes common among these types of drugs.
|
2019 - 2021
|
LJAF
|
|
$343,945
|
To study the feasibility of implementing a patient-reported outcome tool.
|
2021 - 2022
|
LJAF
|
